Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2017
CADTH recommends olaparib following supply of results from phase 3 trial
5 September 2017 - CADTH has published its initial recommendation for olaparib for use as monotherapy maintenance treatment of adult patients ...
Posted by Michael Wonder on 05 Sep 2017
CADTH publishes final outcome for Opdivo for head and neck cancer
5 September 2017 - CADTH has completed its assessment of nivolumab for the treatment of adults with recurrent or metastatic ...
Posted by Michael Wonder on 05 Sep 2017
NICE publishes second draft guidance for ixazomib citrate
5 September 2017 - The Department of Health has asked NICE to produce guidance on use of ixazomib citrate (Ninlaro) in ...
Posted by Michael Wonder on 05 Sep 2017
Introduction of mandatory arrangements for PBS Efficient Funding of Chemotherapy claims
5 September 2017 - From 1 December 2017, approved suppliers will be required to enter a compounder ID when submitting ...
Posted by Michael Wonder on 04 Sep 2017
Merck’s Erbitux backed by NICE for head and neck cancer
4 September 2017 - Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell ...
Posted by Michael Wonder on 04 Sep 2017
US biotech Kite set to be first to launch one-time cancer gene therapy in Britain
3 September 2017 - US biotech Kite is expected to be first out of the blocks in Britain to launch ...
Posted by Michael Wonder on 04 Sep 2017
Analysis of the agenda for the PBAC 2017/3 meeting
4 September 2017 - The PBAC will consider 66 submissions at its next scheduled meeting in early November. ...
Posted by Michael Wonder on 04 Sep 2017
Decision to award sole supply for nicotine replacement therapy
4 September 2017 - PHARMAC is pleased to announce the approval of an agreement with GSK for the supply of ...
Posted by Michael Wonder on 04 Sep 2017
Statistical and clinical significance
4 September 2017 - In published research, a statistically significant result is often wrongly interpreted as representing a clinically important ...
Posted by Michael Wonder on 03 Sep 2017
Health insurers blamed for rising health care costs
4 September 2017 - Australians blame health insurers for rising costs in the nation’s health care system, new consumer research ...
Posted by Michael Wonder on 03 Sep 2017
Call to fund $5000-a-month drug that 'gives people time'
3 September 2017 - A drug that can give patients with advanced breast cancer a longer life has been approved ...
Posted by Michael Wonder on 03 Sep 2017
Nivolumab in squamous cell carcinoma in the head and neck area: additional benefit for certain patients
1 September 2017 - Significant benefit for patients with progression during or shortly after platinum-based therapy. ...
Posted by Michael Wonder on 02 Sep 2017
Commonwealth of Australia v Sanofi: hearing of Commonwealth's claim commences in Federal Court of Australia
31 August 2017 - A six-week hearing in the Federal Court of Australia commenced this week to decide whether the Commonwealth ...
Posted by Michael Wonder on 01 Sep 2017
NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
1 September 2017 - NICE has published draft guidance saying the evidence on using fulvestrant to treat a type of breast ...
Posted by Michael Wonder on 31 Aug 2017
Schedule of Pharmaceutical Benefits - 1 September 2017
1 September 2017 - The September 2017 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...